EurekAlert! -
7 Jan 2020 07:00
(N.N.Aleksandrov National Cancer Center of Belarus) N. N. The Alexandrov National Cancer Centre begins phase II case-control clinical trial of its immuno-oncology agent, Elenagen. Inoperable late-stage cancer patients with triple-negative breast cancer, ovarian cancer, stomach cancer or prostate cancer will be randomized and then subsequently receive either standard chemotherapy or chemotherapy combined with Elenagen.
Share this Article